Education about the recent advances and special considerations associated with the diagnosis and management of transformed indolent lymphomas is essential to facilitate the incorporation of novel treatment options into routine clinical practice to improve clinical outcomes.

The advances in immunotherapy in cancer care are ever-changing and complex. It is integral for nurses to have current knowledge of bispecific antibody therapies in hematologic malignancies and to understand their mechanisms of action and side effect profiles to support optimal patient outcomes.

Learn about the challenges associated with the management of transformed indolent lymphomas and the recent advances in management to help you to incorporate novel therapies into routine clinical practice in the appropriate patient population to improve clinical outcomes.

Learn about the recent advances as well as the challenges involved in the diagnosis and management of classical hairy cell leukemia (HCL) and HCL-variant.

Learn about the challenges associated with the management of transformed indolent lymphomas and the recent advances in management to help you to incorporate novel therapies into routine clinical practice in the appropriate patient population to improve clinical outcomes.

Learn about the recent advances as well as the challenges involved in the diagnosis and management of classical hairy cell leukemia (HCL) and HCL-variant.

Bruton’s tyrosine kinase inhibitors (BTKi) have significantly changed the treatment landscape of B-cell malignancies. A thorough understanding of the mechanism of action (covalent vs. non-covalent), similarities and differences in their safety profile and management of specific treatment-related adverse events will enable clinicians to use these agents safely and effectively in routine clinical practice.

Recent advances in mantle cell lymphoma represent a major paradigm shift. Educating the clinicians about the recent advances and the benefits/risks associated with the use of hematopoietic cell transplant, BTK inhibitors (BTKi) and CAR T-cell therapy can help them make informed clinical decisions for individual patients.

A better understanding of the pathogenesis of hematologic malignancies has led to the identification of new cytogenetic and molecular markers that distinguish between the various subtypes of hematologic malignancies. Informing hematologists and oncologists about the updated WHO5 classification and the new ICC will aid in the accurate diagnosis and development of a treatment plan to the specific subtype of hematologic malignancy.

While cytokine release syndrome and neurotoxicity are widely reported as the most common acute CAR T-cell toxicities, it is essential for providers to understand that CAR T-cell therapy may also result in other toxicities (such as infections, cytopenias, or B-cell aplasia), some of which could persist for months to years after infusion.